CD46 targeted ²¹²Pb alpha particle radioimmunotherapy for prostate cancer treatment.

ABSTRACT: We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated ²¹²Pb, an in vivo generator of alpha-emitting ²¹²Bi and ²¹²Po, to YS5 through the chelator TCMC to create the radioimmunoconjugate, ²¹²Pb-TCMC-YS5. We characterized ²¹²Pb

SUBMITTER: Li J 

PROVIDER: S-EPMC10007843 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature